More Than Low Dose Yellow Paint to Cure
25 Treatments for Babesia: Pharmaceuticals, Herbs, Adjunctive Therapies, and Experimental Approaches
An intervention that kills Babesia in a laboratory is not necessarily effective or safe in a human patient.
Severe babesiosis can cause hemolytic anemia, renal failure, respiratory failure, shock, and death. Evidence-supported antimicrobial treatment and, in selected severe cases, red-cell exchange transfusion take priority over experimental procedures. HBOT, SOT, and EBOO are not established Babesia-eradicating treatments.
The above is according to traditional medicine. I have seen EBOO quickly clear Babesia, but it did not reach all the blood in 60,000 vessels.
Evidence-Supported Pharmaceuticals and Medical Interventions
Evidence Level: Established clinical use unless otherwise indicated.
Atovaquone + Azithromycin
Preferred regimen for most symptomatic patients with uncomplicated babesiosis. Acts against different parasite targets. Human clinical evidence. [1,2]
IN MY 7 BABESIA BOOKS TESTING DOSE-CURE THE STANDARD DOSE IS TOO LOW.
Clindamycin + Quinine
Established alternative regimen; often used in severe disease when clinically appropriate. Quinine can cause substantial adverse effects, including QT prolongation, hypoglycemia, and cinchonism. [1,2]
NOT PLEASENT.
Intravenous Azithromycin + Atovaquone
For selected hospitalized patients with severe disease, IV azithromycin may be used initially, with oral atovaquone when feasible. [1,2]
NOT ROUTINE.
Atovaquone + Azithromycin + Clindamycin
A specialist-directed combination sometimes considered for persistent or relapsing infection in highly immunocompromised patients. Not routine first-line treatment. [1,2]
Atovaquone + Clindamycin
An alternative combination reported in selected refractory cases. Evidence is much more limited than for standard first-line therapy. [1,2]
Atovaquone/Proguanil + Azithromycin
Has been used in selected relapsing or difficult-to-treat cases. Clinical evidence is limited; specialist oversight is necessary. [1,2]
THE SOLID TABLET WITH ATOVOQUONE MAY PREVENT MALARIA BUT OUR 2000’S HUMAN BABESIA RESEARCH SHOWED NO EFFECT. WE USE FOR THE PROQUINIL 100MG [250/100 MG TABLET].
Red-Blood-Cell Exchange Transfusion
Removes infected erythrocytes while replacing them with donor cells. Considered in selected severe cases, including high parasitemia or substantial hemolysis and pulmonary, renal, or hepatic compromise. It supplements rather than replaces antimicrobial treatment. [1,2]
Supportive Treatment for Hemolysis and Organ Failure
Depending on the presentation, this may include transfusion for clinically significant anemia, oxygen or ventilatory support, renal replacement therapy, and hemodynamic support. These measures treat complications, not the parasite directly. [1,2]
The IDSA guideline supports atovaquone plus azithromycin as the preferred regimen and clindamycin plus quinine as the alternative. For highly immunocompromised patients, treatment may require at least six consecutive weeks, including the final two weeks with negative blood smears. Duration must be individualized to the clinical situation. [1,2]
Herbs, Etc.
Herbs and Natural Compounds With Antibabesial Research
These are research candidates, not proven substitutes for prescription treatment. The most relevant paper below evaluated activity against B. duncani in a laboratory model; its results do not establish effective or safe human doses.
Cryptolepis Sanguinolenta
In Vitro Evidence
A botanical extract and its alkaloid cryptolepine inhibited B. duncani in a laboratory erythrocyte model. Some exposed parasites did not regrow under the reported subculture conditions. Human efficacy and safety for babesiosis remain unestablished. [3]
Artemisia Annua
Artemisia annua Hierba seca “Artemisa” – Green Vitality
Experimental
Sweet wormwood extracts showed inhibitory activity against B. duncani in vitro. Whole-herb preparations vary in composition and should not be assumed equivalent to standardized artemisinin medicines. [3]
Artemisia Herba-Alba
Artemisia herba-alba White wormwood plant
Animal and Laboratory Evidence
Extracts inhibited several piroplasm species in vitro. A mouse study also reported enhanced activity against B. microti when the extract was combined with diminazene. Diminazene is not a standard human babesiosis treatment, so this finding is not a clinical regimen. [4]
WE WROTE THE LEADING TEXT ON THIS HERB. IT KILLS MALARIA. IT NEVER KILLS BABESIA IN OUR PUBLISHED HUMAN RESEARCH.
Scutellaria Baicalensis
In Vitro Evidence
Chinese skullcap was among the botanical medicines reported to inhibit B. duncani in vitro. Baicalein, one of its studied constituents, also showed activity. This does not demonstrate that oral supplements achieve antiparasitic concentrations in patients. [3]
Polygonum Cuspidatum
In Vitro Evidence
Japanese knotweed was included among botanical medicines with activity against B. duncani. Resveratrol and other constituents should not automatically be considered responsible for the observed whole-extract effect without compound-specific evidence. [3]
Alchornea Cordifolia
In Vitro Evidence
This botanical extract also demonstrated inhibitory activity against B. duncani in the published laboratory model. Human pharmacokinetics, toxicity, dosing, and clinical effectiveness have not been established. [3]
No known risks in huge use worldwide.
Additional Synthetic or Experimental Antiparasitic Compounds
Artemisinin
Demonstrated in-vitro activity against B. duncani. This is not proof that an artemisinin monotherapy regimen clears human babesiosis. [3]
IT FAILED SCHALLER HUMAN RESEARCH LARGELY. MAY BE USEFUL AS A MAST CELL PATHOLOGY START.
Artesunate
Demonstrated in-vitro antibabesial activity in the B. duncani model. Human babesiosis treatment efficacy is not established. [3]
WRONG. I ESTABLISHED IN HUMANS’ IT DROPS BODY NUMBERS.
Artemether
Showed activity against B. duncani in vitro. The study’s regrowth results are encouraging for research but do not validate clinical use. [3]
THIS IS PRESENT IN COARTEM. I HAVE NO POSITION ON ITS EFFECTIVENESS.
Baicalein
A constituent studied in the B. duncani model, with reported in-vitro activity. Human dosing, safety, and efficacy against babesiosis remain unresolved. [3]
Berberine
Identified among compounds inhibiting B. bovis in a screening study. Activity against a veterinary Babesia species is not proof of efficacy against human B. microti or B. duncani. [5]
NEVER RESEARCHED IN 2000’S.
Other Screened Natural-Product Leads
Compounds including narasin and lasalocid showed activity against B. bovis in research. Their toxicity, veterinary origins, and lack of validated human treatment regimens make them drug-discovery leads rather than clinical options. [5]
HBOT, SOT, EBOO, and Other Adjunctive Approaches
These are included because you specifically requested them. Their inclusion does not mean they are proven treatments for Babesia.
EBOO DROPPED THE VISIBLE NUMBERS IN BLOOD SWEARS OF AN EXTREMELY ILL PATIENT. SMEARS BECAME CLEAR. IT CAME BACK BECAUSE IT DOES NOT KILL ALL 60,000 MILES OF TUBING.
Hyperbaric Oxygen Therapy (HBOT)
Proposed Rationale
Raises dissolved oxygen in plasma and may improve oxygen delivery in selected conditions.
Evidence Assessment
No established clinical evidence that HBOT eradicates human Babesia infection or improves parasite clearance. It must not delay treatment of anemia, hypoxemia, or shock.
Supportive Oligonucleotide Therapy (SOT)
Proposed Rationale
Marketed as a sequence-directed approach intended to target pathogen nucleic acids.
Evidence Assessment
No established, high-quality human clinical evidence validating Babesia-directed SOT for parasite clearance, relapse prevention, or clinical recovery. Laboratory target binding alone would not prove efficacy.
SOME ARE USING.
EBOO (Extracorporeal Blood Oxygenation and Ozonation)
Proposed Rationale
Exposes blood outside the body to an oxygen/ozone process, with claims involving microbial reduction or oxidative effects.
Evidence Assessment
Not an established treatment for babesiosis. There is no convincing clinical evidence that EBOO clears Babesia or improves outcomes.
WRONG. WE PROVEN USEFUL BUT NOT A CURE.
Intravenous Immunoglobulin (IVIG)
Proposed Rationale
Provides pooled antibodies and has immunomodulatory effects.
Evidence Assessment
Not routine antiparasitic treatment. It may be considered for a separate, specific immune-mediated complication in selected cases, but evidence for treating Babesia itself is inadequate.
Immune-Status Optimization and Management of Immunosuppression
Proposed Rationale
Identifies factors associated with persistent or relapsing infection and addresses reversible clinical contributors.
Evidence Assessment
Particularly important in patients with B-cell depletion, hematologic malignancy, transplantation, or other major immune compromise. This is an individualized clinical strategy, not a stand-alone parasite-killing treatment. [1,2]
For HBOT, SOT, and EBOO, the central research question is not simply whether the procedure changes oxygen levels, oxidative markers, or pathogen nucleic acids. It is whether a controlled human study demonstrates a meaningful improvement in parasitemia, sustained clearance, relapse rates, organ outcomes, or survival. I could not identify established clinical evidence supporting those outcomes for these three interventions in human babesiosis.
Full References
Standard Treatment, Exchange Transfusion, and Refractory Infection
Krause PJ, Auwaerter PG, Bannuru RR, et al.
Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis. Clinical Infectious Diseases. 2021;72(2)–e64.
DOI: 10.1093/cid/ciaa1216
Supports treatments 1–8 and 25.
Covers diagnosis, standard antimicrobial combinations, exchange transfusion, and management of immunocompromised patients.
Centers for Disease Control and Prevention
Clinical Care of Babesiosis. Updated February 13, 2024.
CDC clinical guidance.
Supports treatments 1–8 and 25.
Provides clinical treatment regimens, monitoring considerations, and guidance for severe and relapsing infection.
Botanical and Artemisinin Research
Lawres LA, Garg A, Kumar V, et al.
Botanical Medicines Cryptolepis sanguinolenta, Artemisia annua, Scutellaria baicalensis, Polygonum cuspidatum, and Alchornea cordifolia Demonstrate Inhibitory Activity Against Babesia duncani. Pathogens. 2021;10(3):281.
DOI: 10.3390/pathogens10030281
Supports treatments 9, 10, 12–13, and 15–18.
Reports in-vitro activity of botanical extracts and selected constituents against B. duncani.
Evaluation of the In Vitro and In Vivo Inhibitory Effects of Artemisia Herba-Alba Against the Growth of Piroplasm Parasites
Veterinary Parasitology. 2022.
Full article, PubMed Central.
Supports treatment 11.
Examines several Babesia and Theileria species in laboratory experiments and mice.
Drug Discovery and Natural-Product Screening
Discovering the Potent Inhibitors Against Babesia Bovis In Vitro and Babesia Microti In Vivo by Repurposing the Natural Product Compounds
Frontiers in Veterinary Science. 2021;8:762107.
DOI: 10.3389/fvets.2021.762107
Supports treatments 19–20.
Evaluates selected compounds against veterinary Babesia in vitro and B. microti in mice. The results are preliminary and do not establish safe human treatments.
Additional Source for Intravenous Azithromycin + Atovaquone
Centers for Disease Control and Prevention
Clinical Overview of Babesiosis.
CDC clinical overview.
Provides diagnostic context, treatment considerations, and information about severe disease.
Practical Evidence Ranking
| Evidence Category | Treatments | Interpretation |
|---|---|---|
| Established clinical treatment | 1–3, 7–8 | Supported by clinical guidelines; selected treatment depends on severity and patient factors. |
| Specialist-directed refractory treatment | 4–6 | Limited evidence; requires individualized infectious-disease management. |
| Experimental botanicals and compounds | 9–20 | Laboratory or animal findings; not validated substitutes for human treatment. |
| Unproven adjunctive procedures | 21–24 | No established evidence of Babesia eradication or improved clinical outcomes. |
| Management of host risk factors | 25 | Important for persistent or relapsing disease, particularly in immunocompromised patients. |